Bicycle Therapeutics plc American Depositary Shares

Day range

$3.53 – $3.66

Open

$3.56

Prev close

$3.55

Volume

224.9K

Market cap

$248.47M

Shares out

50.55M

P/E

—

P/S

4.06

P/B

0.49

P/FCF

—

ROE

-37.3%

ROA

-31.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Director departureAug 20, 2026

  On August 18, 2026, Charles Swanton resigned as a Class II director of the Board of Directors (the "Board") of Bicycle Therapeutics plc (the "Company"), as a member of the Board's committees and as a member of the Company's Clinical Advisory Board, effective immediately. Dr. Swanton's resignation was for personal reasons and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Annual meeting resultsJun 18, 2026

  Bicycle Therapeutics plc held its annual general meeting of shareholders (the "AGM") on June 17, 2026. Each of the proposals set forth below were voted on and duly passed on a poll at the AGM. There were 49,696,908 ordinary shares of the Company represented in person or by proxy at the AGM, constituting approximately 98.64% of the issued and outstanding ordinary shares on June 17, 2026.

• Clinical trial resultsMay 21, 2026

  On May 21, 2026, Bicycle Therapeutics plc (the "Company") issued a press release announcing initial Duravelo-2 data for metastatic urothelial cancer at the 2026 American Society of Clinical Oncology ("ASCO") Annual Meeting.

• Executive officer appointmentMar 17, 2026

  On March 11, 2026, the Company's Board of Directors appointed Jennifer Perry, Pharm.D. as Chief Operating Officer, effective as of March 17, 2026 (the "Transition Date"). Dr. Perry will succeed Alistair Milnes, who will serve as the Company's Chief Corporate Development Officer, effective as of the Transition Date.

• Executive compensation changeFeb 3, 2026

  Pursuant to Mr. Thompson's employment agreement with BTI, dated January 29, 2026 (the 'Employment Agreement'), Mr. Thompson will receive a base salary of $500,000. Mr. Thompson will also be eligible to receive a target annual cash performance bonus of 50% of his base salary. Mr. Thompson will receive an option to purchase 58,000 of the Company's ordinary shares.

Days to cover

8.7

Short interest

3.3M

Avg volume

378.57K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook
  positiveGlobeNewswire Inc.· Apr 21, 2026
• Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025
  positiveGlobeNewswire Inc.· Aug 29, 2025
• Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director
  neutralGlobeNewswire Inc.· Aug 27, 2025
• Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
  positiveGlobeNewswire Inc.· Mar 3, 2025
• Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
  Zacks Investment Research· Jun 27, 2024